ACAD

AI Memo

ACADIA

As of 2026-08-17/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-08-17 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

—

Confidence

medium

Horizon

—

Key catalyst

Q2 2026 results and guidance increase • 2026-08-04

Base target: $29 / p=55% prob

Biggest risk

The near-term thesis is increasingly dependent on execution against raised guidance and a binary remlifanserin result; a disappointing readout, commercial slowdown, or regulatory delay could pressure the shares. Recent Form 4s also show open-market sales by senior officers, although insider activity is not evidence of operating performance [#SEC-FORM4-2026-08-07] [#SEC-FORM4-2026-07-31].

Invalidation

Break below $21 or thesis failure.

What would change my mind?

Strong DAYBUE and NUPLAZID execution, higher FY2026 revenue guidance, potential European DAYBUE expansion, and a successful remlifanserin readout could support meaningful upside [#SEC-8K-2026-08-04].

Research note

Recommendation

—

Confidence

medium

As of

2026-08-17

Base target

$29

p=55%

Bull target

$38

p=20%

Bear target

$21

p=25%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Execution against raised FY2026 guidance
Remlifanserin Phase 2 Alzheimer’s disease psychosis readout
Potential European authorization for DAYBUE

BearKey bullets

Analyst-count, options, short-interest, social-sentiment, and employee-sentiment data are unavailable, limiting confirmation of market positioning.
DAYBUE and NUPLAZID execution must sustain the increased FY2026 revenue guidance.
European Commission approval of DAYBUE is not guaranteed despite the positive CHMP opinion.

WatchKey bullets

Q2 2026 results and guidance increase

Summary

High-level snapshot

Recommendation

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Base case: $29 (p=55%)

Target spread vs base: +31% / -28%

Scenario probabilities

Bull Target: $38 (p=20%)Base Target: $29 (p=55%)Bear Target: $21 (p=25%)

Commentary

Primary-source tone is constructive after strong Q2 product growth and higher FY2026 guidance, but the earnings event appears largely absorbed by the 2026-08-14 anchor price of $28.24. Incremental upside depends on commercial follow-through and the September-October remlifanserin readout. Social, options, short-interest, and employee data are unavailable; the zero values above denote unavailable measurements, not neutral readings.

As of 2026-08-17 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Strong DAYBUE and NUPLAZID execution, higher FY2026 revenue guidance, potential European DAYBUE expansion, and a successful remlifanserin readout could support meaningful upside [#SEC-8K-2026-08-04].

Bear Case

Drivers

Scannable catalysts and supporting factors

Execution against raised FY2026 guidance
Remlifanserin Phase 2 Alzheimer’s disease psychosis readout
Potential European authorization for DAYBUE

Scenarios

Bull Target (Scenario probability)

$38 / p=20% prob

Base Target (Scenario probability)

$29 / p=55% prob

Bear Target (Scenario probability)

$21 / p=25% prob

Analysis 2026-08-17 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

65.00

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-08-04
Q2 2026 results and guidance increase
Q2 revenue reached $308 million, DAYBUE sales rose 30% to $125 million, NUPLAZID sales rose 10% on an adjusted basis to $183 million, and FY2026 revenue guidance increased to $1.24-$1.30 billion [#8-K-2026-08-04] [#SEC-8K-2026-08-04].
Prob 100.00% • Move 2.00% • Priced-in 90.00%

Short-term Catalysts

Next few weeks

Execution against raised FY2026 guidance
2026-11-15
The higher revenue outlook now requires continued DAYBUE STIX uptake and NUPLAZID momentum; this is an execution watch rather than a confirmed incremental catalyst [#8-K-2026-08-04] [#SEC-8K-2026-08-04].
Prob 60% • Move 4% • Priced-in 65%

Long-term Catalysts

Months to a year

Remlifanserin Phase 2 Alzheimer’s disease psychosis readout
2027-08-17
ACADIA expects topline Phase 2 results in September-October 2026; the Phase 2 portion is enrolled, Phase 3 screening has begun, and Fast Track designation was received, but efficacy remains unconfirmed and the outcome is binary [#8-K-2026-08-04] [#SEC-8K-2026-08-04].
Prob 75% • Move 15% • Priced-in 45%
Potential European authorization for DAYBUE
2027-08-17
The EMA’s CHMP adopted a positive opinion recommending DAYBUE marketing authorization; final European Commission approval remains pending [#SEC-8K-2026-08-04].
Prob 65% • Move 5% • Priced-in 30%

Risks

Analyst-count, options, short-interest, social-sentiment, and employee-sentiment data are unavailable, limiting confirmation of market positioning.
DAYBUE and NUPLAZID execution must sustain the increased FY2026 revenue guidance.
European Commission approval of DAYBUE is not guaranteed despite the positive CHMP opinion.
Remlifanserin Phase 2 efficacy and safety remain unconfirmed, creating material event-driven downside risk.

Peers

Symbol	Summary
CRSP	Same-sector biotechnology comparator near ACAD’s market-cap range; useful for biotech risk-appetite context, but therapeutic and commercial overlap is not established.
DYN	Same-sector biotechnology comparator near ACAD’s market-cap range; a loose biotech-risk comparator rather than a direct operating peer.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-08-17

Loading AI feed…

Symbol

Summary

CRSP

Same-sector biotechnology comparator near ACAD’s market-cap range; useful for biotech risk-appetite context, but therapeutic and commercial overlap is not established.

DYN

Same-sector biotechnology comparator near ACAD’s market-cap range; a loose biotech-risk comparator rather than a direct operating peer.